Ken Griffin Nektar Therapeutics Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nektar Therapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 12,800 shares of NKTR stock, worth $11,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,800

Previous 1,900 573.68%

Holding current value

$11,904

Previous $2,000 700.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $3.39 Million - $6.88 Million	3,761,256 Added 117.77%	6,954,970 $8.62 Million
Q1 2024 May 15, 2024	SELL	$0.49 - $0.96 $1.19 Million - $2.33 Million	-2,431,286 Reduced 43.22%	3,193,714 $2.97 Million
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $2.08 Million - $4.28 Million	-4,078,652 Reduced 42.03%	5,625,000 $3.38 Million
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $3.63 Million - $7.05 Million	6,840,582 Added 238.92%	9,703,652 $5.63 Million
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $627,642 - $3.09 Million	980,692 Added 52.1%	2,863,070 $2 Million
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $1.37 Million - $2.9 Million	677,216 Added 56.19%	1,882,378 $4.25 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $2.21 Million - $3.74 Million	726,812 Added 151.94%	1,205,162 $3.86 Million
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $1.68 Million - $3.28 Million	-531,244 Reduced 52.62%	478,350 $1.82 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $3.45 Million - $11.4 Million	828,363 Added 457.08%	1,009,594 $5.44 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $931,315 - $1.58 Million	85,994 Added 90.29%	181,231 $2.45 Million
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $252,433 - $363,875	-19,314 Reduced 16.86%	95,237 $1.71 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $168,570 - $208,161	10,204 Added 9.78%	114,551 $1.97 Million
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $1.22 Million - $1.87 Million	73,534 Added 238.65%	104,347 $2.09 Million
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $4.09 Million - $4.93 Million	-259,288 Reduced 89.38%	30,813 $524,000
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $3.45 Million - $5.15 Million	-207,826 Reduced 41.74%	290,101 $4.81 Million
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $376,770 - $523,813	22,347 Added 4.7%	497,927 $11.5 Million
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $3.66 Million - $7.07 Million	252,835 Added 113.51%	475,580 $8.49 Million
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $1.13 Million - $1.64 Million	71,087 Added 46.87%	222,745 $4.81 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $656,868 - $1.41 Million	38,845 Added 34.43%	151,658 $2.76 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $5.94 Million - $6.96 Million	-191,755 Reduced 62.96%	112,813 $4.01 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $6.97 Million - $10.2 Million	-220,612 Reduced 42.01%	304,568 $0
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $13.6 Million - $25.3 Million	446,944 Added 571.28%	525,180 $17.3 Million
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $16 Million - $23.6 Million	-344,861 Reduced 81.51%	78,236 $0
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $19.5 Million - $44 Million	421,012 Added 20192.42%	423,097 $0
Q1 2018 May 11, 2018	SELL	$57.4 - $108.44 $1.55 Million - $2.92 Million	-26,941 Reduced 92.82%	2,085 $222,000
Q4 2017 Feb 09, 2018	SELL	$23.02 - $60.5 $2.07 Million - $5.44 Million	-89,917 Reduced 75.6%	29,026 $1.73 Million
Q3 2017 Nov 09, 2017	BUY	$17.79 - $24.0 $2.12 Million - $2.85 Million	118,943	118,943 $2.86 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account